

# Separation of mutation avoidance and antirecombination functions in an *Escherichia coli mutS* mutant

Melissa A. Calmann, Anetta Nowosielska and M. G. Marinus\*

Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA

Received January 5, 2005; Revised and Accepted February 2, 2005

## ABSTRACT

DNA mismatch repair in *Escherichia coli* has been shown to be involved in two distinct processes: mutation avoidance, which removes potential mutations arising as replication errors, and antirecombination which prevents recombination between related, but not identical (homeologous), DNA sequences. We show that cells with the *mutS* $\Delta$ 800 mutation (which removes the C-terminal 53 amino acids of MutS) on a multicopy plasmid are proficient for mutation avoidance. In interspecies genetic crosses, however, recipients with the *mutS* $\Delta$ 800 mutation show increased recombination by up to 280-fold relative to *mutS*<sup>+</sup>. The MutS $\Delta$ 800 protein binds to O<sup>6</sup>-methylguanine mismatches but not to intrastrand platinated GG cross-links, explaining why *dam* bacteria with the *mutS* $\Delta$ 800 mutation are resistant to cisplatin, but not MNNG, toxicity. The results indicate that the C-terminal end of MutS is necessary for antirecombination and cisplatin sensitization, but less significant for mutation avoidance. The inability of MutS $\Delta$ 800 to form tetramers may indicate that these are the active form of MutS.

## INTRODUCTION

The Dam-directed mismatch repair (MMR) system of *Escherichia coli* removes potential mutations arising as replication errors (mutation avoidance) (1–3). Correction of biosynthetic errors by MMR occurs directly after replication, just behind the replication fork, where the parental DNA strand is fully methylated at GATC (*dam*) sequences and the newly synthesized strand is not yet methylated. When base mispairs arise in such hemi-methylated DNA, they are bound

initially by the MutS protein which subsequently recruits MutL and MutH to form a ternary complex. Incision by activated MutH occurs on the unmethylated strand at a nearby GATC sequence, followed by excision, in either the 3' or 5' direction, of the mismatched base pair and surrounding sequence. Re-synthesis by the replicative polymerase, DNA polymerase III, restores the correct nucleotide sequence and the resulting nick is sealed by DNA ligase to complete the repair process. Subsequently, the repaired DNA strand is methylated at GATC sequences by Dam methyltransferase and this methylation prevents further MMR action. This model has both genetic and biochemical support including a mutator phenotype associated with *mutS* mutants (1,2).

MMR also plays a role in preventing recombination between related, but not identical (homeologous), DNA sequences (anti-recombination) (4). Genetic crosses between *E.coli* and *Salmonella enterica* Serovar *Typhimurium* are sterile unless the recipient contains mutations in the *mutS* or *mutL* MMR genes. This result suggests that MMR either impedes or actively reverses recombination intermediates or destroys them, with the former having some experimental support (5–7). On a biochemical level, MutS and MutL block RecA-mediated strand exchange between the fd and M13 genomes, which are 3% divergent, but not between M13–M13 genomes (8). In the homeologous reaction, MutS has a greater effect than MutL, which is effective only in combination with MutS. The intimate connection between mutation avoidance and antirecombination is shown by the phenotype of *E.coli mutS* mutations which are defective in both these processes (4). A survey of a large number of *E.coli mutS* mutants failed to detect any with only one of the phenotypes (9). Similarly, we have been unable to find a mutant with only one of these phenotypes among a collection of dominant-negative alleles (10).

*E.coli dam* mutants are more sensitive to the cytotoxic action of cisplatin and *N*-methyl-*N'*-nitro-*N*-nitrosoguanidine (MNNG) than wild type (11,12). Mutations in genes that

\*To whom correspondence should be addressed. Tel: +1 508 856 3330; Fax: +1 508 856 3036; Email: Martin.Marinus@umassmed.edu

incapacitate MMR (*mutS*, *mutL* or *mutH*) in a *dam* background confer a level of resistance to these agents similar to that of the wild type. This result indicates that inappropriate MMR on chemically modified DNA can sensitize *dam* cells to these cytotoxic agents (11–13). MMR in wild-type cells is restricted to one strand in the hemimethylated region behind the replication fork because MutH endonuclease cannot use fully methylated DNA as a substrate. In *dam* mutants, however, MMR can occur on either strand anywhere on the chromosome because MutH can use unmethylated DNA as a substrate. It has been proposed that MMR-induced single-strand breaks or gaps can be converted to double-strand breaks (DSBs) either by MutH action at the same GATC sequence on the opposite strand (14) or by replication fork collapse (15,16). The DSBs so formed require recombination for their repair thereby making recombination essential for viability (15). As a result of these DSBs, recombination capacity is limiting (15) and when *dam* cells are exposed to cisplatin a large number of DSBs accumulate (16). MMR is required for the formation of cisplatin-induced DSBs (16) suggesting that they probably occur at cisplatin lesions undergoing MMR at either unrepliated lesions or those formed with mismatches after the action of translesion polymerases. The accumulation of DSBs in *dam* mutants, which have limited recombination capacity, and the reduced ability of MutS to prevent RecA-mediated strand transfer of platinated DNA during recombinational repair (17) provides a plausible model to explain why MMR sensitizes *dam* cells to cisplatin.

To explain MMR sensitization of *E.coli dam* mutants by MNNG, the ‘futile cycling’ model was proposed (11). In this model, the replicative polymerase inserts either a T or C opposite template O<sup>6</sup>-methylguanine (O<sup>6</sup>-meG). Since neither of these bases is considered a ‘good’ match by the MMR system, a futile cycle of insertion and removal ensues preventing progression of the replication fork. Such futile cycling in *dam* mutants can also occur at sites away from the replication fork as a consequence of MMR recognition and MutH incision on unmethylated DNA at O<sup>6</sup>-meG–C base pairs to promote DSB formation (13).

The MutS protein binds specifically to heteroduplex DNA containing base mismatches (18) or with greatest affinity to small insertion/deletion loops (IDLs) (19). It also binds platinated GG intrastrand cross-links (20) and O<sup>6</sup>-meG mispaired with either C or T (21). The crystal structure of *E.coli* MutS bound to an oligonucleotide with a G–T mismatch has been solved using a derivative of the MutS protein, MutSΔ800, which lacks the C-terminal 53 amino acids (22). The MutSΔ800 mutant crystallizes as a dimer and retains the ability to bind DNA and ATP, just as full-length MutS does (22). Further analysis into the properties of the MutS and MutSΔ800 proteins by equilibrium sedimentation and gel filtration show that MutS dimers can assemble into higher order oligomeric structures, while the MutSΔ800 mutant is restricted to dimer formation only (23). The ability of MutS to form tetramers suggests this oligomeric state is important in MutS function. A similar conclusion was reached with the MutS protein from *Thermus* species (24,25) for which a crystal structure is also available (26).

In this report, we show that the C-terminal end of MutS is critical for antirecombination and cisplatin sensitization, but less significant for mutation avoidance.

## MATERIALS AND METHODS

### Strains, plasmids and media

Strains GM3819 ( $\Delta$ *dam-16::Kan*), GM4799 (*mutS458::mTn10Kan*), GM5550 (*recA56 mutS458::mTn10Kan*) and GM5556 ( $\Delta$ *dam-16::Kan mutS215::Tn10*) are derivatives of AB1157 (*thr-1 ara-14 leuB6 Δ(gpt-proA)62 lacY1 tsx-33 supE44 galK2 hisG4 rfbD1 mgl-51 rpsL31 kdgK51 xyl-5 mtl-1 argE3 thi-1*). AB259 (HfrH) was obtained from E.A. Adelberg (Yale University). *Salmonella* strains SA536 and SA977 were obtained from the *Salmonella* Genetic Stock Centre, University of Calgary, Canada. Plasmids with the *mutS*ΔC800 (22) (referred to as *mutS*Δ800 in this paper) and *mutS*Δ680 (27) were derived from pMQ372 (27) carrying the *mutS*<sup>+</sup> gene. Full descriptions of strains and plasmids can be found at <http://users.umassmed.edu/martin.marinus/dstrains.html>. Bacteriological media have been described previously (15,28) except for the MacConkey Agar Base (Difco) medium which was supplemented with 50 g/l galactose. Ampicillin, rifampicin and streptomycin were included in media, when required, at 100 μg/ml.

### Estimation of mutant frequency, conjugational crosses and cytotoxicity

Spontaneous mutant frequencies were measured as described elsewhere (28,29) and conjugation experiments were performed as described previously (15) except that mating mixtures were incubated for 1 h at 37°C for homologous crosses and 3 h for the homeologous crosses. Cell survival after exposure to cisplatin or MNNG was measured as described previously (11,29).

### Proteins and DNA

MutS protein was purchased from USB and dialyzed before use against 20 mM KPO<sub>4</sub>, pH 7.4, 0.1 mM EDTA, 1 mM PMSF and 10 mM beta-mercaptoethanol. We found that heteroduplex binding (see below) and ATPase specific activity (data not shown) were the same as that for the MutSΔ800 protein. MutL protein was a gift from F. Lopez de Saro and M. O’Donnell (Rockefeller University). MutSΔ800 was purified from strain GM7854 [*pmutSΔ800/BL21(lamBDE3)*]. Briefly, the cells were grown at 37°C to an OD<sub>600</sub> of 0.8 and shifted to 26°C for induction with 1 mM IPTG. The cells were grown for an additional 3 h at 26°C before harvesting. The cells were lysed using a Microfluidizer (Microfluidics Corp.) and then centrifuged at 27 000 g for 30 min. The supernatant was treated with streptomycin sulfate and ammonium sulfate as described previously (18). The resulting fraction was loaded onto a heparin agarose column (Amersham Pharmacia) and eluted with a linear gradient of 100–400 mM KCl. The fractions containing MutS were subsequently loaded onto a ceramic hydroxylapatite column (Sigma) and eluted using a linear concentration gradient of 20–120 mM KCl. This produced a single MutS peak eluting at 50–70 mM KCl. Fractions containing MutSΔ800 were pooled, concentrated using a Centriprep column (Millipore) and frozen at –75°C. The protein was at least 95% pure as determined by SDS–PAGE analysis. Protein concentration was determined by ninhydrin analysis (30).

M13mp18 DNA RFI and single-stranded circular DNA forms were from New England Biolabs (NEB). The RFI form

was digested with DraIII and BglIII restriction endonucleases (NEB) to remove *lac* operon DNA. Single-stranded circular DNA of bacteriophage fd was prepared by growing a culture of strain AB259 to about  $1 \times 10^8$  cells, adding fd at an m.o.i of 1 and allowing the culture to grow for an additional 3–4 h. The culture was centrifuged to remove bacteria, and 20% polyethyleneglycol 8000 and 2.5 M NaCl solution were added to the supernatant (1:3) and left on ice for 30 min. The mixture was centrifuged at 9500 g for 10 min and the phage pellet resuspended in TE buffer. The DNA was phenol extracted, ethanol precipitated and its concentration determined by UV spectroscopy.

### Heteroduplex construction, electrophoretic mobility shift assay and RecA strand exchange assay

Heteroduplex DNA with a single IDL and labeled with P<sup>32</sup> was constructed and analyzed by electrophoretic mobility shift assay as described previously (19,27). The oligonucleotide 5'-ATACGGAAGTTAAAGT<sup>0</sup>meGCGGATCATCTCTAG-3' (Sigma-Genosys) was annealed with its complementary sequence to form either O<sup>6</sup>meG–C or O<sup>6</sup>meG–T base pairs. A DNA oligonucleotide provided by Jennifer Robbins and J.M. Essigmann (MIT), designated Xlink (5'-CCT CTC CTT GGT CTT CTC CTC TCC-3') contains a cisplatin cross-link between the two guanines and was annealed to its complementary sequence to form either GG–CC or GG–CT mismatches. The platinated and methylated oligonucleotides were not radiolabeled. The P<sup>32</sup>-labeled DNA and the methylated and platinated DNA, which were stained with Vistra Green (Amersham-Pharmacia) for 1 h, were quantitated using a Fuji Phosphorimager. RecA-mediated strand transfer was performed and measured as described except that M13 and fd molecules were used in place of the phiX174 molecules used previously (17).

## RESULTS


### Spontaneous mutation frequency of wild-type and *mutS* strains

Strain GM4799, a *mutS* null mutant (27), was transformed with plasmids bearing the *mutS*<sup>+</sup>, *mutS*Δ680 and *mutS*Δ800 genes. The *mutS*Δ680 and *mutS*Δ800 designations indicate where the 853 amino acid MutS protein was truncated. The *mutS*Δ680 mutation has a null mutator phenotype and the MutSΔ680 protein is unable to form oligomers and has reduced ability to interact with MutL (27). It is used in experiments presented here as the null *mutS* control. The transformed strains were tested for reversion of the *argE3* and *galK2* markers of the host strain as well as resistance to rifampicin. The results in Table 1 and Figure 1 show that the GM4799 strain with the *mutS*Δ800 or *mutS*<sup>+</sup> plasmids did not display a mutator phenotype, but that GM4799 with *mutS*Δ680 plasmid did. The result with rifampicin resistance for the *mutS*Δ800 and *mutS*<sup>+</sup> strains confirmed that obtained previously by Lamers *et al.* (22) and Biswas *et al.* (31). The reversion to Arg<sup>+</sup> and Gal<sup>+</sup> papillae formation was marginally higher in the GM4799 with the *mutS*Δ800 plasmid culture compared to *mutS*<sup>+</sup>, but both these values were much lower than in the *mutS*Δ680 plasmid control strain. We conclude that the *mutS*Δ800 allele does not confer a mutator phenotype to the cell.

**Table 1.** Spontaneous mutant frequencies

Plasmid allele	Arg <sup>+</sup>	Rif <sup>R</sup>
<i>mutS</i> <sup>+</sup>	4	1
<i>mutS</i> Δ680	66	72
<i>mutS</i> Δ800	8	1

Cultures of strain GM4799 (*mutS* null mutation) with the indicated plasmid allele were plated on media selective for rifampicin-resistance or arginine prototrophy. The numbers represent mutant colonies per 10<sup>8</sup> cells plated.



**Figure 1.** Gal reversion assay. Dark Gal<sup>+</sup> revertants are shown on a background of white Gal<sup>-</sup> colonies. From left to right: the GM4799 strain (*mutS* null mutation) with plasmids bearing *mutS*<sup>+</sup>, *mutS*Δ680 and *mutS*Δ800, respectively.

**Table 2.** Yield of recombinants in homologous and homeologous crosses

Donor	Plasmid in recipient	Recipient	Selected marker(s)	Frequency	Fold increase
AB259	<i>mutS</i> <sup>+</sup>	Rec <sup>+</sup>	Thr <sup>+</sup> Leu <sup>+</sup>	$2.8 \times 10^5$	—
AB259	<i>mutS</i> Δ680	Rec <sup>+</sup>	Thr <sup>+</sup> Leu <sup>+</sup>	$2.5 \times 10^5$	1
AB259	<i>mutS</i> Δ800	Rec <sup>+</sup>	Thr <sup>+</sup> Leu <sup>+</sup>	$2.0 \times 10^5$	1
SA536	<i>mutS</i> <sup>+</sup>	Rec <sup>+</sup>	Arg <sup>+</sup>	120	1
SA536	<i>mutS</i> Δ680	Rec <sup>+</sup>	Arg <sup>+</sup>	59 000	492
SA536	<i>mutS</i> Δ800	Rec <sup>+</sup>	Arg <sup>+</sup>	34 000	283
SA977	<i>mutS</i> <sup>+</sup>	Rec <sup>+</sup>	Arg <sup>+</sup>	35	1
SA977	<i>mutS</i> Δ680	Rec <sup>+</sup>	Arg <sup>+</sup>	10 665	296
SA977	<i>mutS</i> Δ800	Rec <sup>+</sup>	Arg <sup>+</sup>	3410	100
SA536	<i>mutS</i> <sup>+</sup>	<i>recA56</i>	Arg <sup>+</sup>	30	1
SA536	<i>mutS</i> Δ680	<i>recA56</i>	Arg <sup>+</sup>	80	2.7
SA536	<i>mutS</i> Δ800	<i>recA56</i>	Arg <sup>+</sup>	60	2
SA977	<i>mutS</i> <sup>+</sup>	<i>recA56</i>	Arg <sup>+</sup>	8	1
SA977	<i>mutS</i> Δ680	<i>recA56</i>	Arg <sup>+</sup>	120	15
SA977	<i>mutS</i> Δ800	<i>recA56</i>	Arg <sup>+</sup>	85	10

Donor and recipient (GM4799 and GM5550) cultures (at  $1-2 \times 10^8$  cells per ml) were mated for 60 min (AB259) or 3 h (SA strains). The numbers in the table represent the Thr<sup>+</sup> Leu<sup>+</sup> [Str<sup>R</sup>] or Arg<sup>+</sup> [Str<sup>R</sup>] recombinants in 50 μl of undiluted mating mixture.

### Interspecies crosses

Strain GM4799 with each of the *mutS* plasmids was used as a recipient in conjugal crosses with *E.coli* (homologous) or *S.enterica* Serovar *Typhimurium* (homeologous) donors. With the *E.coli* donor, AB259, recombinants were formed after 60 min of mating, at the same frequency with each GM4799 strain indicating no effect of the *mutS* alleles on homologous recombination (Table 2). With the *Salmonella* donors SA536 or SA977, however, the GM4799 recipient with the *mutS*Δ800 plasmid formed recombinants 283- and 100-fold higher than the wild-type recipient, respectively. These values, however, are about half that for the GM4799 strain with the *mutS*Δ680 plasmid indicating that the *mutS*Δ800 allele does not completely relieve the inhibition produced by a fully proficient MMR system. The level of homeologous recombination was



the same with either strain GM4799 or GM4799 containing the *mutSΔ680* plasmid (data not shown).

To ensure that the results of the crosses described above were due to recombination, we repeated the crosses with a recombination-deficient (*recA56*) derivative of GM4799, GM5550. With the *E.coli* donor, AB259, no recombinants were detected in any of the crosses with the GM5550 recipients (data not shown). With the *Salmonella* donors, there was more than a 99% decrease in recombinant formation in the GM5550 strains with the *mutSΔ800* and *mutSΔ680* plasmids. We conclude that the *mutSΔ800* mutation significantly reduces antirecombination in interspecies crosses in a *recA*-dependent manner.

### Sensitivity to cytotoxic agents

*E.coli dam* mutants are more sensitive to cisplatin and MNNG than wild type (11,12). Figure 2A shows that a *dam mutS* strain, GM5556, carrying the *mutS<sup>+</sup>* plasmid is more sensitive to cisplatin than the same strain bearing the *mutSΔ680* (null mutation) plasmid or the *mutSΔ800* plasmid, indicating that the *mutSΔ800* gene product is unable to promote MMR sensitization. Figure 2A also shows that the survival of GM3819, a *dam mutS<sup>+</sup>* strain, with the *mutSΔ800* plasmid is the same as with a *mutS<sup>+</sup>* plasmid. This result indicates that the *mutSΔ800* allele in multicopy does not have a dominant-negative phenotype in wild-type (*mutS<sup>+</sup>*) cells.


Figure 2B shows that when exposed to MNNG, the GM5556 strain with the *mutS<sup>+</sup>* plasmid is sensitive but that with the *mutSΔ680* plasmid is resistant. In contrast to the results with cisplatin, GM5556 with the *mutSΔ800* plasmid has the same survival as the strain with the *mutS<sup>+</sup>* plasmid.

The simplest interpretation of the data in Figure 2 is that while the MutSΔ800 protein is unable to recognize diguanyl platinated cross-links, it can recognize O<sup>6</sup>-meG mismatches with enough efficiency to produce the same phenotype in cells as MutS.


### MutS and MutSΔ800 binding to platinated oligonucleotides

To investigate if MutS and MutSΔ800 have altered binding to cisplatin cross-links, we tested the ability of both proteins to


bind to homoduplex, heteroduplex and platinated DNA substrates in an electrophoretic mobility shift assay. The data in Figure 3 show that MutSΔ800 has approximately the same affinity for P<sup>32</sup>-labeled heteroduplex DNA with a single base



**Figure 3.** Binding isotherm of MutS and MutSΔ800 to heteroduplex DNA. The upper panel shows the binding of MutS and MutSΔ800 to a P<sup>32</sup>-labeled heteroduplex DNA with a single base IDL. The heteroduplex concentration was 0.6 pmol. The data are shown in the lower panel as a binding isotherm.



**Figure 2.** Survival of cells exposed to cisplatin and MNNG. Cell survival of strain GM5556 ( $\Delta dam-16::Kan mutS::Tn10$ ) containing plasmids with *mutS<sup>+</sup>* (closed circles), *mutSΔ680* (inverted triangles), and *mutSΔ800* (closed squares) after exposure to cisplatin (A) and MNNG (B). The open squares in (A) represent the survival of GM3819 ( $\Delta dam-16::Kan mutS^+$ ) with the *mutSΔ800* plasmid.



**Figure 4.** Binding of MutS and MutS $\Delta$ 800 to modified DNA. (A) The binding of MutS and MutS $\Delta$ 800 to unplatinated (lanes 1–5) and platinated homoduplex (lanes 6–10) DNA. No enzyme (lanes 1 and 6); MutS, 8  $\mu$ M (lanes 2 and 7) and 4  $\mu$ M (lanes 3 and 8); and MutS $\Delta$ 800, 8  $\mu$ M (lanes 4 and 9) and 4  $\mu$ M (lanes 5 and 10). The DNA was visualized by staining the gel with Vistra Green. (B) The binding of MutS and MutS $\Delta$ 800 to unplatinated (lanes 1–5) and platinated heteroduplex (lanes 6–10). Protein additions are the same as in (A). (C) The binding of MutS and MutS $\Delta$ 800 to O<sup>6</sup>-meG–C (lanes 1–4) and O<sup>6</sup>-meG–T (lanes 5–8) DNA. MutS, 8  $\mu$ M (lanes 1 and 5) and 16  $\mu$ M (lanes 2 and 6); and MutS $\Delta$ 800, 8  $\mu$ M (lanes 3 and 7) and 16  $\mu$ M (lanes 4 and 8).

IDL as MutS. There was no significant binding of these proteins to a fully base-paired homoduplex substrate under the same experimental conditions (data not shown).

The substrates for MutS binding to platinated DNA included unplatinated homoduplex DNA, unplatinated heteroduplex DNA with a G–T mismatch, and derivatives of each of these with a single intrastrand diguanyl cross-link (Figure 4). The unplatinated homoduplex acts as a negative control for the diguanyl cross-link paired with CC, and is considered to be a biologically relevant adduct produced from the reaction of cisplatin and DNA. The GG–CT substrate acts as a positive control ensuring that MutS can bind to mismatched DNA in this sequence context. The mobility shifts shown in Figure 4 were monitored by fluorescence after staining with Vistra Green. As expected, there was no detectable band shifting with MutS and MutS $\Delta$ 800 to unplatinated homoduplex DNA at the concentrations used for specific binding (Figure 4A, lanes 2–5). In contrast to the results in Figure 3, where MutS and MutS $\Delta$ 800 bind the IDL with near equivalent affinity, we did detect a difference in binding between MutS and MutS $\Delta$ 800 to the unplatinated heteroduplex containing a G–T mismatch (Figure 4B, lanes 2–5). The addition of 4  $\mu$ M of MutS produced a discernible retardation of the oligonucleotide (lane 3) while, at the same concentration, MutS $\Delta$ 800 did not (lane 5). At this concentration, MutS forms two distinct bands (lane 3), only one of which is present with MutS $\Delta$ 800 (lane 5) and may indicate that MutS first binds as a dimer and subsequently is converted to a tetramer. With 8  $\mu$ M, the extent of heteroduplex binding by MutS $\Delta$ 800 was about 80% that of MutS (lanes 2 and 4).

There was a significant difference in binding of MutS and MutS $\Delta$ 800 to DNA with a GG cross-link opposite two C residues (Figure 4A, lanes 6–10). In fact, no binding of MutS $\Delta$ 800 to this DNA was observed (Figure 4A, lanes 9 and 10) although MutS, at the same concentration, did produce a considerable band shift (Figure 4A, lanes 7 and 8). On the other hand, the DNA with a GG cross-link opposite CT residues, a product of translesion polymerase synthesis, was bound by MutS $\Delta$ 800 to about the same extent as MutS at 4 nM but less so at 8 nM due to partial shifting (Figure 4B,

lanes 6–10). With this substrate, the MutS and MutS $\Delta$ 800 upper bands are at about the same location. This could be due to MutS $\Delta$ 800 recognizing this substrate as a G–T mismatch and the presence of the platinated guanines or that MutS $\Delta$ 800 arrays on this substrate to a greater extent than MutS.

The results in Figure 4C show that both MutS and MutS $\Delta$ 800 were able to bind to a duplex DNA with a single O<sup>6</sup>-meG–C (lanes 1–4) or O<sup>6</sup>-meG–T (lanes 5–8). There was no binding to homoduplex DNA at the concentrations used (data not shown). The difference in the binding affinities of MutS $\Delta$ 800 for the types of heteroduplexes used in Figures 3 and 4 are relevant because the affinity of these proteins for the same substrate can differ due to sequence context or the type of mismatch or the affinity for base mismatches versus a one base IDL.


MutS $\Delta$ 800, therefore, has impaired specific binding of platinated intrastrand GG–CC cross-links, but not intrastrand GG–CT cross-links or a single base IDL or O<sup>6</sup>-meG–C or O<sup>6</sup>-meG–T mismatches. Since MutS can form tetramers while MutS $\Delta$ 800 cannot, this suggests that the ability to form tetramers could be necessary for efficient MutS processing of the biologically relevant platinated intrastrand cross-link.

#### RecA-mediated strand exchange *in vitro*

In this assay, the ability of MutS to inhibit RecA-mediated strand transfer between M13–M13 (homologous) and M13–fd (homeologous) phage DNA molecules is measured (8). Figure 5 shows the results of a typical assay. For the M13–M13 homologous substrates (lanes a–e), nicked circle (NC) product and intermediate (I) bands are visible after 5 min (lane b) and these increase and decrease, respectively, during the reaction (lanes c–e). The homeologous M13–fd reaction (lanes f–j), is clearly slower, with no nicked circle product visible at 5 min (lane g) and a lower yield (72%) at 90 min (lane j). The graph in Figure 6 shows that the addition of 100 nM MutS or MutS $\Delta$ 800 has no effect on the rate or yield of the reaction using the homologous M13–M13 substrates. Addition of 25 or 100 nM MutS, however, reduces exchange between homeologous M13–fd substrates by 48%

and 98%, respectively (Figure 6A). When MutS $\Delta$ 800 is added, the corresponding percentages were 22% and 58%, respectively (Figure 6B).

Worth *et al.* (8) showed that MutL stimulates MutS binding to M13-fd homeologous duplexes when the latter is at a sub-optimal concentration. In the experiment shown in Figure 6, 25 nM MutS or MutS $\Delta$ 800 only partially inhibits RecA-catalyzed strand transfer. Inclusion of MutL, at 15 or 40 nM to these reactions, however, completely abolishes RecA transfer activity (Figure 6) indicating that MutL dimers can interact with MutS or MutS $\Delta$ 800. MutL by itself had no effect on the




**Figure 5.** RecA-catalyzed strand transfer. The upper panel shows a schematic diagram of the reaction. Single-strand (SS) circular DNA reacts with linear (L) duplex to form intermediate (I) structures which are converted into nicked-circle (NC) products. The fluorograph shows the results from the homologous M13-M13 (lanes a-e) and the homeologous M13-fd (lanes f-j) reactions. Samples were removed at time 0 (lanes a and f), 5 min (lanes b and g), 15 min (lanes c and h), 45 min (lanes d and i) and 90 min (lanes e and j).

rate or product yield in the reaction. We showed previously that there was no binding of MutL alone to platinated cross-linked DNA (17).

## DISCUSSION

The results described in this report show that MutS and MutS $\Delta$ 800 proteins, produced from multicopy plasmids, impart different properties to cells. Although cells with the MutS $\Delta$ 800 or MutS protein are not mutators (Table 1 and Figure 1), the MutS $\Delta$ 800-containing cells are deficient in antirecombination (Table 2) and not sensitized to cisplatin cytotoxicity (Figure 2A). This is the first demonstration of a separation of function phenotype for an *E. coli mutS* mutation. We propose that the C-terminal domain of MutS is required for efficient antirecombination and cisplatin sensitization, but not mutation avoidance or MNNG sensitization. Given that MutS $\Delta$ 800 can only form monomers and dimers, we postulate that the inability to form tetrameric MutS could be responsible for this phenotype. The data reported here also suggests that although MutS and MutS $\Delta$ 800 may bind base mismatches as dimers, conversion to the tetrameric form may be required for subsequent reactions in mismatch repair.

The results we have obtained in this report are best explained by the findings of Bjornson *et al.* (23) who have argued that the MutS tetramer is likely the active form of MutS in mutation avoidance. To support this conclusion, they found that MutS $\Delta$ 800 protein bound to mismatched DNA less efficiently than MutS. Our results also indicate that MutS $\Delta$ 800 does have reduced affinity for GG-CT base mismatches (Figure 4B) but not with the one base IDL (Figure 3) or O<sup>6</sup>-meG mismatches (Figure 4C). Given that MutS $\Delta$ 800 has reduced affinity for some base mismatches, we propose that the lack of a mutator phenotype in cells over-expressing MutS $\Delta$ 800 (Table 1 and Figure 1) can be explained by the MutS dimer being able to cope with the few mismatches generated behind the replication fork. The atomic structure of MutS $\Delta$ 800 indicates that mismatch binding does occur.



**Figure 6.** Kinetics of MutS inhibition of RecA-mediated strand exchange. The graphs show the effect of varying concentrations of MutS (A) and MutS $\Delta$ 800 (B) on RecA strand exchange using homologous (M13-M13) and homeologous (M13-fd). Closed circles, M13-M13; crosses, M13-M13 plus 100 nM protein; closed squares, M13-fd; open squares, M13-fd plus 25 nM protein; open circles, M13-fd plus 100 nM protein; and inverted triangles, M13-fd plus 25 nM protein plus 40 nM MutL.

In interspecies crosses, however, the much larger number of mismatches overwhelms the MutS $\Delta$ 800 protein's reduced mismatch binding and processing ability, thereby leading to reduced antirecombination as shown in Table 2. An essential part of our proposal, therefore, is that the cell's response with dimeric MutS depends on the number of mismatches involved; if there are few, overproduced dimeric MutS can substitute for tetrameric MutS at its normal cellular concentration. The data in Figures 5 and 6, showing a greater amount of M13-fd heteroduplex formation by MutS $\Delta$ 800 compared to MutS, is consistent with this model. The combination of MutL and MutS $\Delta$ 800 is as effective as MutS and MutL where the level of mismatching is 3%. We predict that at higher levels of mismatching, such as the 17% in *E.coli*-*Salmonella* crosses, MutS $\Delta$ 800 would be much less effective than MutS, even in the presence of MutL.

Bjornson *et al.* (23) also showed that MutH-induced incision of heteroduplex DNA, in the presence of MutL, was reduced by MutS $\Delta$ 800. This observation can also help to explain the response of *dam* mutants with the over-expressed MutS $\Delta$ 800 protein to cisplatin and MNNG. For cells exposed to MNNG, there is sufficient binding of MutS $\Delta$ 800 to O<sup>6</sup>-meG mismatches to provoke a sensitization response even though there is reduced MutH-induced incision (Figure 2B). For *dam* cells expressing MutS $\Delta$ 800 and exposed to cisplatin, however, the reduced binding of MutS $\Delta$ 800 to intrastrand diguanylcisplatin cross-links and the reduced MutH-induced incision activity allow the cell to repair, by recombination, the few DSBs that might be formed (Figure 2B).

The model proposed above regarding the number of mismatched base pairs and the ability of over-expressed MutS $\Delta$ 800 to deal with them makes the strong prediction that when MutS $\Delta$ 800 is expressed from a single-copy gene, the *dam* cells containing it would have different responses for spontaneous mutagenesis and resistance to cisplatin and MNNG compared to expression from a multicopy plasmid. Experiments to test this prediction are in progress.

Surprisingly, MutS $\Delta$ 800 when expressed in a wild-type background does not display a dominant negative phenotype with regard to cisplatin sensitivity (Figure 2). This result appears to rule out the possibility that MutS, which is at a low cellular concentration, could be titrated out by the plasmid expressed MutS $\Delta$ 800, leading to a dominant negative phenotype. We have not yet quantitated the protein levels of the plasmid expressed MutS $\Delta$ 800 versus the chromosomally expressed copy of MutS. If the MutS $\Delta$ 800 protein is less stable than MutS, then the ratio of the two proteins may be such that active mixed multimers are formed allowing for near-full functionality of the protein (Figure 2), which is absent in a population containing only the MutS $\Delta$ 800.

The results in Figure 4 indicate that the C-terminal end of MutS is required for binding to platinated GG-CC cross-links, which could also indicate a requirement for MutS tetramerization, in that the dimeric MutS $\Delta$ 800 cannot recognize the lesion, whereas the MutS does. At present, it is not known how this cross-link opposite CC differs in structure from that opposite CT to allow efficient recognition by MutS, but it is possible that binding to a platinated lesion requires critical contacts with residues residing in the C-terminus of MutS, offering an alternative to the tetramerization requirement. Furthermore, deletion of the C-terminus may disrupt the

binding of MutS to low-affinity lesions, such as the intrastrand GG cross-links (10- to 40-fold lower than a G-T mismatch (20,23), but not to a high affinity one base IDL (Figure 3). Either explanation is supported by the survival results for cells with the *mutS* $\Delta$ 800 plasmid exposed to cisplatin (Figure 2). In addition to these alternatives to tetramerization, we cannot rule out a critical loss of interaction(s) between MutS $\Delta$ 800 and other proteins, such as the beta-clamp (32) which can ultimately affect the efficiency of recognition or repair processes.

That MutS can bind to platinated GG-CC cross-links suggests that MMR-induced DSBs can occur in unreplicated DNA of *dam* mutants at these sequences, as well as cross-links opposite CT bases, which can be formed by translesion polymerases (33,34). Platinated GG-CC cross-links can also be formed during recombinational repair of DSBs and these are bound by MutS which can block further branch migration (17), thereby preventing DSB repair. The ability of MutS to bind these cross-links can explain the observed cisplatin sensitivity of the *dam mutS*<sup>+</sup> strain in Figure 2A. In contrast, the decreased binding of MutS $\Delta$ 800 to such lesions reduces the number of mismatch repair-induced DSBs and thereby promotes survival of the *dam mutS* $\Delta$ 800 strain to cisplatin (Figure 2A).

Finally, we note that mammalian cell lines also show sensitivity to cisplatin and MNNG and MMR-deficient lines derived from them are resistant to both compounds (35,36), although whether cisplatin resistance is due specifically to MMR-deficiency has recently been challenged (37,38). Cisplatin-resistant cells isolated from patients treated with this drug have also been shown to be deficient in MMR (39). Like the bacterial MutS protein, the human MutS-alpha counterpart also binds to cisplatin intrastrand cross-links and O<sup>6</sup>-meG mismatches (40). The various models proposed to explain mismatch repair-dependent drug-resistance in mammalian cells have been reviewed in (41). The data reported here with *E.coli* MutS $\Delta$ 800 have no counterpart in eukaryotic systems, thereby preventing selection of one model over another.

## ACKNOWLEDGEMENTS

We thank Meindert Lamers and Titia Sixma for the *mutS* $\Delta$ C800 plasmid; Kenneth Sanderson for the *Salmonella* donor strains; Jennifer Robbins for construction and purification of the cross-linked platinated oligonucleotide; Dianne Schwarz for assistance with the radiolabeled band shifts; F. Lopez de Saro and M. O'Donnell for the gift of MutL protein and Mary Munson for invaluable help and guidance during protein purification. This work was supported by grant GM63790 from the National Institutes of Health. Funding to pay the Open Access publication charges for this article was provided by the National Institutes of Health.

## REFERENCES

1. Modrich,P. and Lahue,R. (1996) Mismatch repair in replication fidelity, genetic recombination, and cancer biology. *Annu. Rev. Biochem.*, **65**, 101-133.
2. Schofield,M.J. and Hsieh,P. (2003) DNA mismatch repair: molecular mechanisms and biological function. *Annu. Rev. Microbiol.*, **57**, 579-608.
3. Marti,T.M., Kunz,C. and Fleck,O. (2002) DNA mismatch repair and mutation avoidance pathways. *J. Cell Physiol.*, **191**, 28-41.



4. Rayssiguier, C., Thaler, D.S. and Radman, M. (1989) The barrier to recombination between *Escherichia coli* and *Salmonella typhimurium* is disrupted in mismatch-repair mutants. *Nature*, **342**, 396–401.
5. Westmoreland, J., Porter, G., Radman, M. and Resnick, M.A. (1997) Highly mismatched molecules resembling recombination intermediates efficiently transform mismatch repair proficient *Escherichia coli*. *Genetics*, **145**, 29–38.
6. Harfe, B.D. and Jinks-Robertson, S. (2000) DNA mismatch repair and genetic instability. *Annu. Rev. Genet.*, **34**, 359–399.
7. Fabisiowicz, A. and Worth, L., Jr (2001) *Escherichia coli* MutS, L modulate RuvAB-dependent branch migration between diverged DNA. *J. Biol. Chem.*, **276**, 9413–9420.
8. Worth, L., Clark, S.R.M. and Modrich, P. (1994) Mismatch repair proteins MutS and MutL inhibit RecA-catalyzed strand transfer between diverged DNAs. *Proc. Natl Acad. Sci. USA*, **91**, 3238–3241.
9. Junop, M.S., Yang, W., Funchain, P., Clendenin, W. and Miller, J.H. (2003) *In vitro* and *in vivo* studies of MutS, MutL and MutH mutants: correlation of mismatch repair and DNA recombination. *DNA Repair (Amst.)*, **2**, 387–405.
10. Wu, T.H. and Marinus, M.G. (1994) Dominant negative mutator mutations in the *mutS* gene of *Escherichia coli*. *J. Bacteriol.*, **176**, 5393–5400.
11. Karran, P. and Marinus, M.G. (1982) Mismatch correction at O<sup>6</sup>-methylguanine residues in *E. coli* DNA. *Nature*, **296**, 868–869.
12. Fram, R.J., Cusick, P.S., Wilson, J.M. and Marinus, M.G. (1985) Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage. *Mol. Pharmacol.*, **28**, 51–55.
13. Marinus, M.G. (2005) Dr Jekyll and Mr Hyde: how the MutSLH repair system kills the cell. In Higgins, N.P. (ed.), *The Bacterial Chromosome*. ASM Press, Washington, DC, pp. 413–430.
14. Au, K.G., Welsh, K. and Modrich, P. (1992) Initiation of methyl-directed mismatch repair. *J. Biol. Chem.*, **267**, 12142–12148.
15. Marinus, M.G. (2000) Recombination is essential for viability of an *Escherichia coli dam* (DNA adenine methyltransferase) mutant. *J. Bacteriol.*, **182**, 463–468.
16. Nowosielska, A. and Marinus, M.G. (2005) Cisplatin induces DNA double-strand break formation in *Escherichia coli dam* mutants. *DNA Repair (Amst.)*, in press.
17. Calmann, M.A. and Marinus, M.G. (2004) MutS inhibits RecA-mediated strand exchange with platinated DNA substrates. *Proc. Natl Acad. Sci. USA*, **101**, 14174–14179.
18. Su, S.S. and Modrich, P. (1986) *Escherichia coli mutS*-encoded protein binds to mismatched DNA base pairs. *Proc. Natl Acad. Sci. USA*, **83**, 5057–5061.
19. Parker, B.O. and Marinus, M.G. (1992) Repair of DNA heteroduplexes containing small heterologous sequences in *Escherichia coli*. *Proc. Natl Acad. Sci. USA*, **89**, 1730–1734.
20. Fourrier, L., Brooks, P. and Malinge, J.M. (2003) Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein. *J. Biol. Chem.*, **278**, 21267–21275.
21. Rasmussen, L.J. and Samson, L. (1996) The *Escherichia coli* MutS DNA mismatch binding protein specifically binds O(6)-methylguanine DNA lesions. *Carcinogenesis*, **17**, 2085–2088.
22. Lamers, M.H., Perrakis, A., Enzlin, J.H., Winterwerp, H.H., de Wind, N. and Sixma, T.K. (2000) The crystal structure of DNA mismatch repair protein MutS binding to a G × T mismatch. *Nature*, **407**, 711–717.
23. Bjornson, K.P., Blackwell, L.J., Sage, H., Baitinger, C., Allen, D. and Modrich, P. (2003) Assembly and molecular activities of the MutS tetramer. *J. Biol. Chem.*, **278**, 34667–34673.
24. Takamatsu, S., Kato, R. and Kuramitsu, S. (1996) Mismatch DNA recognition protein from an extremely thermophilic bacterium, *Thermus thermophilus* HB8. *Nucleic Acids Res.*, **24**, 640–647.
25. Biswas, I., Ban, C., Fleming, K.G., Qin, J., Lary, J.W., Yphantis, D.A., Yang, W. and Hsieh, P. (1999) Oligomerization of a MutS mismatch repair protein from *Thermus aquaticus*. *J. Biol. Chem.*, **274**, 23673–23678.
26. Obmolova, G., Ban, C., Hsieh, P. and Yang, W. (2000) Crystal structures of mismatch repair protein MutS and its complex with a substrate DNA. *Nature*, **407**, 703–710.
27. Wu, T.H. and Marinus, M.G. (1999) Deletion mutation analysis of the *mutS* gene in *Escherichia coli*. *J. Biol. Chem.*, **274**, 5948–5952.
28. Marinus, M.G. and Morris, N.R. (1974) Biological function for 6-methyladenine residues in the DNA of *Escherichia coli* K12. *J. Mol. Biol.*, **85**, 309–322.
29. Nowosielska, A., Calmann, M.A., Zdravski, Z., Essigmann, J.M. and Marinus, M.G. (2004) Spontaneous and cisplatin-induced recombination in *Escherichia coli*. *DNA Repair (Amst.)*, **3**, 719–728.
30. Rosen, H. (1957) A modified ninhydrin colorimetric analysis for amino acids. *Arch. Biochim. Biophys.*, **67**, 10–15.
31. Biswas, I., Obmolova, G., Takahashi, M., Herr, A., Newman, M.A., Yang, W. and Hsieh, P. (2001) Disruption of the helix–u-turn–helix motif of MutS protein: loss of subunit dimerization, mismatch binding and ATP hydrolysis. *J. Mol. Biol.*, **305**, 805–816.
32. Lopez de Saro, F.J. and O'Donnell, M. (2001) Interaction of the beta sliding clamp with MutS, ligase, and DNA polymerase I. *Proc. Natl Acad. Sci. USA*, **98**, 8376–8380.
33. Vaisman, A. and Chaney, S.G. (2000) The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta. *J. Biol. Chem.*, **275**, 13017–13025.
34. Vaisman, A., Masutani, C., Hanaoka, F. and Chaney, S.G. (2000) Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. *Biochemistry*, **39**, 4575–4580.
35. Branch, P., Masson, M., Aquilina, G., Bignami, M. and Karran, P. (2000) Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. *Oncogene*, **19**, 3138–3145.
36. Kartalou, M. and Essigmann, J.M. (2001) Mechanisms of resistance to cisplatin. *Mutat. Res.*, **478**, 23–43.
37. Massey, A., Offman, J., Macpherson, P. and Karran, P. (2003) DNA mismatch repair and acquired cisplatin resistance in *E. coli* and human ovarian carcinoma cells. *DNA Repair (Amst.)*, **2**, 73–89.
38. Claij, N. and Te Riele, H. (2004) Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells. *Oncogene*, **23**, 260–266.
39. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R.D. and Howell, S.B. (1996) The role of DNA mismatch repair in platinum drug resistance. *Cancer Res.*, **56**, 4881–4886.
40. Duckett, D.R., Drummond, J.T., Murchie, A.I., Reardon, J.T., Sancar, A., Lilley, D.M. and Modrich, P. (1996) Human MutSalpha recognizes damaged DNA base pairs containing O<sup>6</sup>-methylguanine, O<sup>4</sup>-methylthymine, or the cisplatin-d(GpG) adduct. *Proc. Natl Acad. Sci. USA*, **93**, 6443–6447.
41. Stojic, L., Brun, R. and Jiricny, J. (2004) Mismatch repair and DNA damage signalling. *DNA Repair (Amst.)*, **3**, 1091–1101.